Original Title: Agentes biológicos en pacientes con espondiloartritis

Authors' recommendations: CONCLUSIONS Moderate-quality evidence shows that adalimumab, etanercept, infliximab, certolizumab, golimumab (antitumor necrosis factor-alpha, anti-TNF) and secukinumab are effective in controlling active ankylosing spondylitis in adults with inadequate response or intolerance to non-steroidal anti-inflammatory drugs (NSAIDs). Moderate-quality evidence shows the effectiveness of adalimumab, etanercept, certolizumab and golimumab in patients with non-radiologic axial spondyloarthritis and inadequate response or intolerance to NSAIDS. It is worth noting that infliximab has not been approved by the main drug regulatory agencies for these indications and the other four anti-TNFs have not been approved by the US Food and Drug Administration (FDA), but they have been approved by the Argentine National Food, Drug and Medical Technology Administration (ANMAT) and the European Medicine Agency (EMA). Moderate-quality evidence shows that adalimumab, etanercept, infliximab, certolizumab, golimumab, ustekinumab and secukinumab are effective in controlling active peripheral arthritis despite treatment with conventional drugs in patients with psoriatic arthritis while low-quality evidence suggests the usefulness of some of these drugs in patients with psoriatic arthritis and enthesitis or dactylitis. The clinical practice guidelines consulted recommend the use of most of these drugs in the above mentioned conditions and situations as well as in patients with axial involvement resulting from psoriatic arthritis, extrapolating the available evidence in patients with axial spondyloarthritis. The health sponsors consulted, both public and private from around the world, cover most of these therapies in these groups of patients. Since there seem to be no significant differences in the effects these drugs have, many organizations decide which one or which ones are covered or reimbursed taking their cost into account. No local cost-effectiveness, financial impact and organization studies have been found so the impact is uncertain in this aspect.

Project Status: Completed

Year Published: 2017

URL for published report: https://www.iecs.org.ar/home-ets/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Argentina

Organisation Name: Institute for Clinical Effectiveness and Health Policy

Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA

Contact Name: info@iecs.org.ar

Contact Email: info@iecs.org.ar

Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)